APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antibody Drug Conjugates (ADCs)

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Antibody Drug Conjugates (ADCs) Market Outlook and Growth Opportunities 2026

20 December 2025194 pages

Choose your research edition.

Industry ResearchAntibody Drug Conjugates (ADCs) Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Antibody Drug Conjugates (ADCs) Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Antibody Drug Conjugates (ADCs) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antibody Drug Conjugates (ADCs) Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Antibody Drug Conjugates (ADCs) Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Antibody Drug Conjugates (ADCs) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Antibody Drug Conjugates (ADCs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Antibody Drug Conjugates (ADCs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antibody Drug Conjugates (ADCs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Antibody Drug Conjugates (ADCs) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Antibody Drug Conjugates (ADCs) market include AbGenomics, ADC Therapeutics, Astellas Pharma, Genmab, Kairos Therapeutics, Seattle Genetics, Takeda Pharmaceuticals, AbbVie and Bayer, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Antibody Drug Conjugates (ADCs) market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Antibody Drug Conjugates (ADCs) and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Antibody Drug Conjugates (ADCs) revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Antibody Drug Conjugates (ADCs) market.

Antibody Drug Conjugates (ADCs) Segment by Company

AbGenomics

ADC Therapeutics

Astellas Pharma

Genmab

Kairos Therapeutics

Seattle Genetics

Takeda Pharmaceuticals

AbbVie

Bayer

Pfizer

Roche

Novartis

Antibody Drug Conjugates (ADCs) Segment by Type

Seattle Genetics Technology

Immunomedics Technology

ImmunoGen Technology

Antibody Drug Conjugates (ADCs) Segment by Application

Hospital

Clinics

Others

Antibody Drug Conjugates (ADCs) Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Antibody Drug Conjugates (ADCs) status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Antibody Drug Conjugates (ADCs) key companies, revenue, market share, and recent developments.

3. To split the Antibody Drug Conjugates (ADCs) breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Antibody Drug Conjugates (ADCs) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Antibody Drug Conjugates (ADCs) significant trends, drivers, influence factors in global and regions.

6. To analyze Antibody Drug Conjugates (ADCs) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antibody Drug Conjugates (ADCs) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antibody Drug Conjugates (ADCs) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antibody Drug Conjugates (ADCs).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Antibody Drug Conjugates (ADCs) industry.

Chapter 3: Detailed analysis of Antibody Drug Conjugates (ADCs) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Antibody Drug Conjugates (ADCs) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Antibody Drug Conjugates (ADCs) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Antibody Drug Conjugates (ADCs) Industry Trends Table 2. Antibody Drug Conjugates (ADCs) Industry Drivers Table 3. Antibody Drug Conjugates (ADCs) Industry Opportunities and Challenges Table 4. Antibody Drug Conjugates (ADCs) Industry Restraints Table 5. Global Antibody Drug Conjugates (ADCs) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Antibody Drug Conjugates (ADCs) Revenue Share by Company (2021-2026) Table 7. Global Antibody Drug Conjugates (ADCs) Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Antibody Drug Conjugates (ADCs) Key Company Manufacturing Base & Headquarters Table 9. Global Antibody Drug Conjugates (ADCs) Company, Product Type & Application Table 10. Global Antibody Drug Conjugates (ADCs) Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Antibody Drug Conjugates (ADCs) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Seattle Genetics Technology Table 15. Significant Companies of Immunomedics Technology Table 16. Significant Companies of ImmunoGen Technology Table 17. Global Antibody Drug Conjugates (ADCs) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Antibody Drug Conjugates (ADCs) Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Antibody Drug Conjugates (ADCs) Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Antibody Drug Conjugates (ADCs) Sales Value Share by Type (2021-2026) Table 21. Global Antibody Drug Conjugates (ADCs) Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Hospital Table 23. Significant Companies of Clinics Table 24. Significant Companies of Others Table 25. Global Antibody Drug Conjugates (ADCs) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Antibody Drug Conjugates (ADCs) Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Antibody Drug Conjugates (ADCs) Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Antibody Drug Conjugates (ADCs) Sales Value Share by Application (2021-2026) Table 29. Global Antibody Drug Conjugates (ADCs) Sales Value Share by Application (2027-2032) Table 30. Global Antibody Drug Conjugates (ADCs) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Antibody Drug Conjugates (ADCs) Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Antibody Drug Conjugates (ADCs) Sales Value Share by Region (2021-2026) Table 33. Global Antibody Drug Conjugates (ADCs) Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Antibody Drug Conjugates (ADCs) Sales Value Share by Region (2027-2032) Table 35. Global Antibody Drug Conjugates (ADCs) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Antibody Drug Conjugates (ADCs) Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Antibody Drug Conjugates (ADCs) Sales Value Market Share by Country (2021-2026) Table 38. Global Antibody Drug Conjugates (ADCs) Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Antibody Drug Conjugates (ADCs) Sales Value Market Share by Country (2027-2032) Table 40. AbGenomics Company Information Table 41. AbGenomics Business Overview Table 42. AbGenomics Antibody Drug Conjugates (ADCs) Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. AbGenomics Antibody Drug Conjugates (ADCs) Product Portfolio Table 44. AbGenomics Recent Development Table 45. ADC Therapeutics Company Information Table 46. ADC Therapeutics Business Overview Table 47. ADC Therapeutics Antibody Drug Conjugates (ADCs) Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. ADC Therapeutics Antibody Drug Conjugates (ADCs) Product Portfolio Table 49. ADC Therapeutics Recent Development Table 50. Astellas Pharma Company Information Table 51. Astellas Pharma Business Overview Table 52. Astellas Pharma Antibody Drug Conjugates (ADCs) Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Astellas Pharma Antibody Drug Conjugates (ADCs) Product Portfolio Table 54. Astellas Pharma Recent Development Table 55. Genmab Company Information Table 56. Genmab Business Overview Table 57. Genmab Antibody Drug Conjugates (ADCs) Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Genmab Antibody Drug Conjugates (ADCs) Product Portfolio Table 59. Genmab Recent Development Table 60. Kairos Therapeutics Company Information Table 61. Kairos Therapeutics Business Overview Table 62. Kairos Therapeutics Antibody Drug Conjugates (ADCs) Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Kairos Therapeutics Antibody Drug Conjugates (ADCs) Product Portfolio Table 64. Kairos Therapeutics Recent Development Table 65. Seattle Genetics Company Information Table 66. Seattle Genetics Business Overview Table 67. Seattle Genetics Antibody Drug Conjugates (ADCs) Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Seattle Genetics Antibody Drug Conjugates (ADCs) Product Portfolio Table 69. Seattle Genetics Recent Development Table 70. Takeda Pharmaceuticals Company Information Table 71. Takeda Pharmaceuticals Business Overview Table 72. Takeda Pharmaceuticals Antibody Drug Conjugates (ADCs) Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Takeda Pharmaceuticals Antibody Drug Conjugates (ADCs) Product Portfolio Table 74. Takeda Pharmaceuticals Recent Development Table 75. AbbVie Company Information Table 76. AbbVie Business Overview Table 77. AbbVie Antibody Drug Conjugates (ADCs) Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. AbbVie Antibody Drug Conjugates (ADCs) Product Portfolio Table 79. AbbVie Recent Development Table 80. Bayer Company Information Table 81. Bayer Business Overview Table 82. Bayer Antibody Drug Conjugates (ADCs) Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Bayer Antibody Drug Conjugates (ADCs) Product Portfolio Table 84. Bayer Recent Development Table 85. Pfizer Company Information Table 86. Pfizer Business Overview Table 87. Pfizer Antibody Drug Conjugates (ADCs) Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Pfizer Antibody Drug Conjugates (ADCs) Product Portfolio Table 89. Pfizer Recent Development Table 90. Roche Company Information Table 91. Roche Business Overview Table 92. Roche Antibody Drug Conjugates (ADCs) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Roche Antibody Drug Conjugates (ADCs) Product Portfolio Table 94. Roche Recent Development Table 95. Novartis Company Information Table 96. Novartis Business Overview Table 97. Novartis Antibody Drug Conjugates (ADCs) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Novartis Antibody Drug Conjugates (ADCs) Product Portfolio Table 99. Novartis Recent Development Table 100. Research Programs/Design for This Report Table 101. Authors List of This Report Table 102. Secondary Sources Table 103. Primary Sources List of Figures Figure 1. Antibody Drug Conjugates (ADCs) Product Image Figure 2. Global Antibody Drug Conjugates (ADCs) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antibody Drug Conjugates (ADCs) Market Size (2021-2032) & (US$ Million) Figure 4. Global Antibody Drug Conjugates (ADCs) Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Seattle Genetics Technology Image Figure 8. Immunomedics Technology Image Figure 9. ImmunoGen Technology Image Figure 10. Global Antibody Drug Conjugates (ADCs) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Antibody Drug Conjugates (ADCs) Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Antibody Drug Conjugates (ADCs) Sales Value Share by Type (2021-2032) Figure 13. Hospital Image Figure 14. Clinics Image Figure 15. Others Image Figure 16. Global Antibody Drug Conjugates (ADCs) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Antibody Drug Conjugates (ADCs) Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Antibody Drug Conjugates (ADCs) Sales Value Share by Application (2021-2032) Figure 19. Global Antibody Drug Conjugates (ADCs) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Antibody Drug Conjugates (ADCs) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Antibody Drug Conjugates (ADCs) Sales Value (2021-2032) & (US$ Million) Figure 22. North America Antibody Drug Conjugates (ADCs) Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Antibody Drug Conjugates (ADCs) Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Antibody Drug Conjugates (ADCs) Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Antibody Drug Conjugates (ADCs) Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Antibody Drug Conjugates (ADCs) Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Antibody Drug Conjugates (ADCs) Sales Value (2021-2032) & (US$ Million) Figure 28. South America Antibody Drug Conjugates (ADCs) Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Antibody Drug Conjugates (ADCs) Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Antibody Drug Conjugates (ADCs) Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Seattle Genetics Technology
  • Immunomedics Technology
  • ImmunoGen Technology
Applications
  • Hospital
  • Clinics
  • Others
Companies covered
  • AbGenomics
  • ADC Therapeutics
  • Astellas Pharma
  • Genmab
  • Kairos Therapeutics
  • Seattle Genetics
  • Takeda Pharmaceuticals
  • AbbVie
  • Bayer
  • Pfizer
  • Roche
  • Novartis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Antibody Drug Conjugates (ADCs) Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Antibody Drug Conjugates (ADCs) Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Antibody Drug Conjugates (ADCs) Market Dynamics
  1. 2.1 Antibody Drug Conjugates (ADCs) Industry Trends
  2. 2.2 Antibody Drug Conjugates (ADCs) Industry Drivers
  3. 2.3 Antibody Drug Conjugates (ADCs) Industry Opportunities and Challenges
  4. 2.4 Antibody Drug Conjugates (ADCs) Industry Restraints
3 Antibody Drug Conjugates (ADCs) Market by Company
  1. 3.1 Global Antibody Drug Conjugates (ADCs) Company Revenue Ranking in 2025
  2. 3.2 Global Antibody Drug Conjugates (ADCs) Revenue by Company (2021-2026)
  3. 3.3 Global Antibody Drug Conjugates (ADCs) Company Ranking (2024-2026)
  4. 3.4 Global Antibody Drug Conjugates (ADCs) Company Manufacturing Base and Headquarters
  5. 3.5 Global Antibody Drug Conjugates (ADCs) Company Product Type and Application
  6. 3.6 Global Antibody Drug Conjugates (ADCs) Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Antibody Drug Conjugates (ADCs) Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Antibody Drug Conjugates (ADCs) Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Antibody Drug Conjugates (ADCs) Market by Type
  1. 4.1 Antibody Drug Conjugates (ADCs) Type Introduction
  2. 4.1.1 Seattle Genetics Technology
  3. 4.1.2 Immunomedics Technology
  4. 4.1.3 ImmunoGen Technology
  5. 4.2 Global Antibody Drug Conjugates (ADCs) Sales Value by Type
  6. 4.2.1 Global Antibody Drug Conjugates (ADCs) Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Antibody Drug Conjugates (ADCs) Sales Value by Type (2021-2032)
  8. 4.2.3 Global Antibody Drug Conjugates (ADCs) Sales Value Share by Type (2021-2032)
5 Antibody Drug Conjugates (ADCs) Market by Application
  1. 5.1 Antibody Drug Conjugates (ADCs) Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinics
  4. 5.1.3 Others
  5. 5.2 Global Antibody Drug Conjugates (ADCs) Sales Value by Application
  6. 5.2.1 Global Antibody Drug Conjugates (ADCs) Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Antibody Drug Conjugates (ADCs) Sales Value by Application (2021-2032)
  8. 5.2.3 Global Antibody Drug Conjugates (ADCs) Sales Value Share by Application (2021-2032)
6 Antibody Drug Conjugates (ADCs) Regional Value Analysis
  1. 6.1 Global Antibody Drug Conjugates (ADCs) Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Antibody Drug Conjugates (ADCs) Sales Value by Region (2021-2032)
  3. 6.2.1 Global Antibody Drug Conjugates (ADCs) Sales Value by Region: 2021-2026
  4. 6.2.2 Global Antibody Drug Conjugates (ADCs) Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Antibody Drug Conjugates (ADCs) Sales Value (2021-2032)
  7. 6.3.2 North America Antibody Drug Conjugates (ADCs) Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Antibody Drug Conjugates (ADCs) Sales Value (2021-2032)
  10. 6.4.2 Europe Antibody Drug Conjugates (ADCs) Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Antibody Drug Conjugates (ADCs) Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Antibody Drug Conjugates (ADCs) Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Antibody Drug Conjugates (ADCs) Sales Value (2021-2032)
  16. 6.6.2 South America Antibody Drug Conjugates (ADCs) Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Antibody Drug Conjugates (ADCs) Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Antibody Drug Conjugates (ADCs) Sales Value Share by Country, 2025 VS 2032
7 Antibody Drug Conjugates (ADCs) Country-level Value Analysis
  1. 7.1 Global Antibody Drug Conjugates (ADCs) Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Antibody Drug Conjugates (ADCs) Sales Value by Country (2021-2032)
  3. 7.2.1 Global Antibody Drug Conjugates (ADCs) Sales Value by Country (2021-2026)
  4. 7.2.2 Global Antibody Drug Conjugates (ADCs) Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Antibody Drug Conjugates (ADCs) Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Antibody Drug Conjugates (ADCs) Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Antibody Drug Conjugates (ADCs) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 AbGenomics
  2. 8.1.1 AbGenomics Company Information
  3. 8.1.2 AbGenomics Business Overview
  4. 8.1.3 AbGenomics Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (2021-2026)
  5. 8.1.4 AbGenomics Antibody Drug Conjugates (ADCs) Product Portfolio
  6. 8.1.5 AbGenomics Recent Developments
  7. 8.2 ADC Therapeutics
  8. 8.2.1 ADC Therapeutics Company Information
  9. 8.2.2 ADC Therapeutics Business Overview
  10. 8.2.3 ADC Therapeutics Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (2021-2026)
  11. 8.2.4 ADC Therapeutics Antibody Drug Conjugates (ADCs) Product Portfolio
  12. 8.2.5 ADC Therapeutics Recent Developments
  13. 8.3 Astellas Pharma
  14. 8.3.1 Astellas Pharma Company Information
  15. 8.3.2 Astellas Pharma Business Overview
  16. 8.3.3 Astellas Pharma Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Astellas Pharma Antibody Drug Conjugates (ADCs) Product Portfolio
  18. 8.3.5 Astellas Pharma Recent Developments
  19. 8.4 Genmab
  20. 8.4.1 Genmab Company Information
  21. 8.4.2 Genmab Business Overview
  22. 8.4.3 Genmab Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Genmab Antibody Drug Conjugates (ADCs) Product Portfolio
  24. 8.4.5 Genmab Recent Developments
  25. 8.5 Kairos Therapeutics
  26. 8.5.1 Kairos Therapeutics Company Information
  27. 8.5.2 Kairos Therapeutics Business Overview
  28. 8.5.3 Kairos Therapeutics Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Kairos Therapeutics Antibody Drug Conjugates (ADCs) Product Portfolio
  30. 8.5.5 Kairos Therapeutics Recent Developments
  31. 8.6 Seattle Genetics
  32. 8.6.1 Seattle Genetics Company Information
  33. 8.6.2 Seattle Genetics Business Overview
  34. 8.6.3 Seattle Genetics Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Seattle Genetics Antibody Drug Conjugates (ADCs) Product Portfolio
  36. 8.6.5 Seattle Genetics Recent Developments
  37. 8.7 Takeda Pharmaceuticals
  38. 8.7.1 Takeda Pharmaceuticals Company Information
  39. 8.7.2 Takeda Pharmaceuticals Business Overview
  40. 8.7.3 Takeda Pharmaceuticals Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Takeda Pharmaceuticals Antibody Drug Conjugates (ADCs) Product Portfolio
  42. 8.7.5 Takeda Pharmaceuticals Recent Developments
  43. 8.8 AbbVie
  44. 8.8.1 AbbVie Company Information
  45. 8.8.2 AbbVie Business Overview
  46. 8.8.3 AbbVie Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (2021-2026)
  47. 8.8.4 AbbVie Antibody Drug Conjugates (ADCs) Product Portfolio
  48. 8.8.5 AbbVie Recent Developments
  49. 8.9 Bayer
  50. 8.9.1 Bayer Company Information
  51. 8.9.2 Bayer Business Overview
  52. 8.9.3 Bayer Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Bayer Antibody Drug Conjugates (ADCs) Product Portfolio
  54. 8.9.5 Bayer Recent Developments
  55. 8.10 Pfizer
  56. 8.10.1 Pfizer Company Information
  57. 8.10.2 Pfizer Business Overview
  58. 8.10.3 Pfizer Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Pfizer Antibody Drug Conjugates (ADCs) Product Portfolio
  60. 8.10.5 Pfizer Recent Developments
  61. 8.11 Roche
  62. 8.11.1 Roche Company Information
  63. 8.11.2 Roche Business Overview
  64. 8.11.3 Roche Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Roche Antibody Drug Conjugates (ADCs) Product Portfolio
  66. 8.11.5 Roche Recent Developments
  67. 8.12 Novartis
  68. 8.12.1 Novartis Company Information
  69. 8.12.2 Novartis Business Overview
  70. 8.12.3 Novartis Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Novartis Antibody Drug Conjugates (ADCs) Product Portfolio
  72. 8.12.5 Novartis Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst